June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Identifying physiological biomarkers intermediating DME treatment
Author Affiliations & Notes
  • Charlotte E Joslin
    Ophthalmology/Visual Sciences, University Illinois at Chicago, Chicago, Illinois, United States
    Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, Illinois, United States
  • Jacob K Kresovich
    Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, Illinois, United States
  • Norman P Blair
    Ophthalmology/Visual Sciences, University Illinois at Chicago, Chicago, Illinois, United States
  • Mahnaz Shahidi
    Ophthalmology/Visual Sciences, University Illinois at Chicago, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Charlotte Joslin, None; Jacob Kresovich, None; Norman Blair, None; Mahnaz Shahidi, None
  • Footnotes
    Support  NIH research grants DK104393, EY001792 and Research to Prevent Blindness
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 919. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Charlotte E Joslin, Jacob K Kresovich, Norman P Blair, Mahnaz Shahidi; Identifying physiological biomarkers intermediating DME treatment. Invest. Ophthalmol. Vis. Sci. 2017;58(8):919.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intravitreal anti-VEGF treatment (IVT) improves best corrected visual acuity (BCVA) and decreases central subfield thickness (CST) in diabetic macular edema. Pre-treatment mean arterial blood pressure and retinal arterial oxygen saturation (SO2A) significantly predicts IVT treatment outcomes (BCVA, CST), but mechanisms of IVT have not been elucidated. We examined pathophysiologic measurements as potential mechanisms through which IVT affects BCVA and CST in a prospective observational study.

Methods : We assessed nine biomarkers, BCVA and CST at baseline and follow-up in 50 eyes of 29 subjects with non-proliferative diabetic retinopathy (NPDR) or proliferative (PDR). We performed oximetry using a commercial scanning laser ophthalmoscope (Optos200TX) and measured retinal arterial and venous oxygen saturation of hemoglobin (SO2A, SO2V), central retinal artery and vein equivalents (CRAE, CRVE), retinal arterial and venous caliber (CalA, CalV), and oxygen extraction fraction (OEF). CST was measured with optical coherence tomography (Heidelberg) and BCVA with ETDRS protocols. We used multivariable mixed effect linear regression models with random intercepts, accounting for two eyes per subject, to assess the effects of treatment on each biomarker at longitudinal follow-up, adjusting for age, race, sex, prior IVT injections and DR diagnosis. We additionally assessed the adjusted cross-sectional effects of each biomarker on BCVA and CST at follow-up, further adjusting for lifetime IVT injections (Figure).

Results : Median follow-up was 116 days. Twenty-six eyes received IVT after enrollment. In longitudinal analyses, compared to non-treated eyes, IVT was associated with a decreases in CRAE (β=-9.1, p= 0.09), SO2A (β=-10.4, p= 0.09), and OEF (β=-0.1, p= 0.01), and increases in SO2V (β=6.0, p=0.08). In cross-sectional analyses, for every unit change per biomarker, there was an associated change in CST (β=-2.0, p=0.01 for SO2V; β=130.4, p=0.02 for OEF; β=0.7, p=0.06 for CRVE; β=1.7, p=0.06 for CalV) and in BCVA (β=0.1, p=0.08 for CRAE; β=0.1, p=0.12 for SO2V).

Conclusions : Results suggest three biomarkers (SO2V, OEF and CRAE) are intermediaries between IVT and treatment outcomes. This study was limited by the small sample size; we therefore considered marginal results as meaningful. These results elucidate pathways through which IVT improves visual outcomes via pathophysiologic mechanisms.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×